Stockpolly
Search
Delisting risk
GNPX · NASDAQ · Biotechnology

Genprex (GNPX)

Develops REQORSA for lung cancer and GPX-002 for diabetes.

$3.51
Pre-market+0.01 (+0.29%)
At close$3.50(−1.41%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue000000000000
Gross profit000000000000
866744453444
Research & development543233322233
323521121122
Selling & marketing000000000000
General & administrative003000121122
Operating income−8−6−6−7−4−4−4−5−3−4−4−4
000000000000
Interest income000000000000
Interest expense000000000000
Other non-operating income000000000000
Income before tax−8−6−6−6−4−4−4−5−4−4−4−4
Net income from continuing operations−8−6−6−6−4−4−4−5−4−4−4−4
Net income−8−6−6−6−4−4−4−5−4−4−4−4
EPS, basic−$268.00−$4,389.00−$4,059.00−$3,300.00−$1,353.00−$462.00−$286.00−$187.00−$110.00−$25.30−$14.08−$9.40
EPS, diluted−$268.00−$4,389.00−$4,059.00−$3,300.00−$1,353.00−$462.00−$286.00−$187.00−$110.00−$25.30−$14.08−$9.40
Weighted average shares, basic000000000000
Weighted average shares, diluted000000000000
EBITDA−8−6−6−6−4−4−4−5−3−4−4−4
Depreciation & amortization000000000000
EBIT−8−6−6−6−4−4−4−5−3−4−4−4